Valeant Pharmaceuticals International announced that William D. Humphries has been appointed executive vice president, dermatology, effective January 2, 2017. He will join Valeant’s Executive Committee, reporting directly to the company’s chairman and CEO, Joseph C. Papa.
Humphries has nearly 30 years of experience in the dermatology and specialty pharmaceuticals industry. He joins Valeant from Merz, where he most recently served as CEO of its North America business. Prior to Merz, Humphries served as president of Stiefel, now a subsidiary of GlaxoSmithKline, and held multiple senior roles at Allergan.
“We are pleased to welcome another experienced leader to our team,” said Papa. “Bill has an unparalleled understanding of the dermatology and aesthetics space and a proven track record of successfully developing and commercializing products in these therapeutic areas. We look forward to his contributions as we continue working toward a recovery of our core prescription dermatology business.”
Valeant also announced that Anne Whitaker, EVP and company group chairman, has decided to leave the company on January 13, 2017. Rob Rosiello will depart the company as well on December 31, 2016. He previously served as the Valeant CFO from July 2015 through August 2016 and has successfully transitioned the role to Valeant’s new CFO, Paul Herendeen. Ari Kellen, EVP and company group chairman, will also depart Valeant on December 31, 2016. Kellen and Rosiello will continue to serve as consultants on an ongoing basis. “I sincerely thank Anne, Rob and Ari for their contributions to Valeant and appreciate their efforts to stabilize the company during a period of transition,” said Papa. “We wish them well in the future.”
